Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity

Bibliography

• SCHWARTZ MW, WOODS SC, PORTE D Jr., SEELEY RJ, BASKIN DG: Central nervous system control of food intake. Nature (2000) 404:661–671.
   Google Scholar
• CHEN H, CHARLAT 0, TARTAGLIA LA et al: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/ db mice. Cell (1996) 84:491–495.
   PubMed Web of Science ®Google Scholar
• PHILLIPS MS, LIU Q, HAMMOND HA et al: Leptin receptor missense mutation in the fatty Zucker rat. Nat. Cm (1996) 13:18–19.
   Google Scholar
• ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD L, FRIEDMAN JM: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372:425–432.
   PubMed Web of Science ®Google Scholar
• ELMQUIST JK, MARATOS-FLIER E, SAPER CB, FLIER JS: Unravelling the central nervous system pathways underlying responses to leptin. Nat. Neurosci. (1998) 1:445–450.
   PubMed Web of Science ®Google Scholar
• FAROOQI IS, JEBB SA, LANGMACK G et al: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl. j. Med. (1999) 341:879–884.
   PubMed Web of Science ®Google Scholar
• HEYMSFIELD SB, GREENBERG AS, FUJI OKA K et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J. Am. Med. Assoc. (1999) 282:1568–1575.
   Google Scholar
• HUKSHORN CJ, SARIS WH, WESTERTERP-PLANTENGA MS, FARID AR, SMITH FJ, CAMPFIELD LA: Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. j. Endocnhol. Metab. (2000) 85:4003–4009.
   PubMed Web of Science ®Google Scholar
• CAMPFIELD LA, SMITH FJ, BURN P: Strategies and potential molecular targets for obesity treatment. Science (1998) 280:1383–1387.
   PubMed Web of Science ®Google Scholar
• BILLINGTON CJ, BRIGS JE, GRACE M, LEVINE AS: Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am. Physiol (1991) 260:R321–R327.
   Google Scholar
• STANLEY BG, MAGDALIN W, SEIRAFI A, NGUYEN MM, LEIBOWITZ SF: Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y1 receptor mediating this peptide's effect. Peptides (1992) 13:581–587.
   PubMed Web of Science ®Google Scholar
• CLARK JT, KALRA PS, CROWLEY WR et al.: Neuropeptide Y and pancreatic polypeptide stimulates feeding behavior in rats. Endocrinology (1984) 115:427–429.
   PubMed Web of Science ®Google Scholar
• CLARK JT, KALRA PS, CROWLEY WR et al.: Neuropeptide Y stimulates feeding, but inhibits sexual behavior in rats. Endocrinology (1985) 117:2435–2442.
   PubMed Web of Science ®Google Scholar
• AKABAYASHI A, WAHLESTEDT C, ALEXANDER JT, LEIBOWITZ SF: Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppress feeding behavior and insulin secretion. Mol. Brain Res. (1994) 21:55–61.
   PubMedGoogle Scholar
• DUBE MG, XU B, CROWLEY WR, KALRA PS, KALRA SP: Evidence that neuropeptide Y is a physiological signal for normal food intake. Blain Res. (1994) 646:341–344.
   Google Scholar
• STEPHENS TW, BASINSKI M, BRISTOW PK et al: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature (1995) 77:530–532.
   Google Scholar
• WILDING JPH, GILBEY SG, BAILEY CJ et al.: Increased neuropeptide Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology (1993) 132:1939–1944.
   PubMed Web of Science ®Google Scholar
• ERICKSON JC, HOLLOPETER G, PALMITER RD: Attenuation of the obesity syndromes of ob/ob mice by the loss of neuropeptide Y. Science (1996) 274:1704–1707.
   PubMed Web of Science ®Google Scholar
• BLOMQVIST AG, HERZOG H: Y-receptor subtypes-how many more? Trends Neurosci. (1997) 20:294–298.
   Google Scholar
• GERALD C, WALKER MW, CRISCIONE L et al: A receptor subtype involved in neuropeptide-Y-induced food intake. Nature (1996) 382:168–171.
   PubMed Web of Science ®Google Scholar
• KASK A, RAGO L, HARRO J: Evidence forinvolvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. Br. Pharmacol (1998) 124:1507–1515.
   PubMed Web of Science ®Google Scholar
• WIELAND HA, ENGEL W, EBERLEIN W, RUDOLF K, DOODS HN: Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIB03304 and its effect on feeding in rodents. Br .j Pharmacol. (1998) 125:549–555.
   PubMed Web of Science ®Google Scholar
• JACQUES D, CADIEUX A, DUMONT Y, QUIRION R: Apparent affinity and potency of BIBP3226, a non-peptide neuropeptide Y receptor antagonist, on purported neuropeptide Y Yl, Y2 and Y3 receptor: Eur. j Pharmacol (1995) 278:R3–R5.
   Google Scholar
• O'SHEA D, MORGAN DG, MEERAN K et al: Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology (1997) 138:196–202.
   PubMed Web of Science ®Google Scholar
• HIPSKIND P, LOBB KL, NIXON JA etal.: Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. I Med. Chem. (1997) 40:3712–3714.
   Google Scholar
• ZARRINMAYEH H, NUNES AM, ORNSTEIN PL et al.: Synthesis and evaluation of a series of novel 24(4-chlorophenoxy)methyll-benzimidazoles as selective neuropeptide Y Y1 receptor antagonists. I Med. Chem. (1998) 41:2709–2719.
   PubMed Web of Science ®Google Scholar
• BRITTON TC, SPINAZZE PG, HIPSKIND PA et al: Structure-activity relationship of a series of benzothiophene-derived NPY Y1 antagonists: optimization of the C-2 side chain. Bioorg. Med. Chem. Lett. (1999) 9:475–480.
   PubMed Web of Science ®Google Scholar
• ZARRINMAYEH H, ZIMMERMAN DM, CANTRELL BE etal.: Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists. Bioorg. Med. Chem. Lett. (1999) 9:647–652.
   Google Scholar
• KANATANI A, KANNO T, ISHIHARA A et al: The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem. Biophys. Res. Commun. (1999) 266:88–91.
   PubMed Web of Science ®Google Scholar
• KANNO T, KANATANI A, KEEN SL et al.: Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors. Peptides (2001) 22:405–413.
   PubMedGoogle Scholar
• MURAKAMI Y, HAGISHITA S, OKADA T et al.: 1,3-disubstituted benzazepines as neuropeptide Y Y1 receptor antagonist. Bioorg. Med. Chem. (1999) 8:1703–1714.
   Google Scholar
• KANATANI A, HATA M, MASHIKO S et al.: A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol. Pharmacol. (2001) 59:501–505.
   PubMed Web of Science ®Google Scholar
• RUEEGER H, RIGOLLIER P, YAMAGUCHI Y et al: Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazol neuropeptide Y Y5 receptor antagonists. Bioorg. Med. Chem. Lett. (2000) 10:1175–1179.
   PubMedGoogle Scholar
• PATCHETT AA, NARGUND RP TATA JR etal.: Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc. Natl. Acad. ScL USA (1995) 92:7001–7005.
   Google Scholar
• KANATANI A, ISHIHARA A, IWAASA H et al.: L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem. Biophys. Res. Commun. (2000) 272:169–173.
   PubMedGoogle Scholar
• NORMAN MH, CHEN N, CHEN Z et al.: Structure-activity relationship of a series of pyrrolor3,2-dlpyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists. j Med. Chem. (2000) 43:4288–4312.
   PubMed Web of Science ®Google Scholar
• TATEMOTO T, ROEKAEUS A, JORWALL H, MCDONALD TJ, MUTT V: Galanin-a novel biologically active peptide from porcine intestine. FEBS Lett.(1983) 164:124–128.
   PubMed Web of Science ®Google Scholar
• SKOFITSCH G, SILLS MA, JACOBOWITZ DM: Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system. Peptides (1986) 7:1029–1042.
   PubMedGoogle Scholar
• KYRKOULI SE, STANLEY BG, LEIBOWITZ SF: Galanin: stimulation of feeding induced by medial hypothalamic injection. Eur. PharmacoL (1986) 122:159–160.
   PubMed Web of Science ®Google Scholar
• TEMPEL DL, LEIBOWITZ KJ, LEIBOWITZ SF: Effects of PVN galanin on macronutrient selection. Peptides (1988) 9:309–314.
   PubMed Web of Science ®Google Scholar
• AKABAYASHI A, KOENIG JI, WATANABE Y, ALEXANDER JT, LEIBOWITZ SF: Galanin-containing neurons in the paraventricular nucleus: a neurochemical marker for fat ingestion and body weight gain. Proc. Natl. Acad. ScL USA (1994) 91:10375–10379.
   PubMed Web of Science ®Google Scholar
• LEIBOWITZ SF, KIM T: Impact of a galanin antagonist on exogenous galanin and natural patterns of fat ingestion. Brain Res. (1992) 599:148–152.
   PubMed Web of Science ®Google Scholar
• WYNICK D, SMALL CJ, BACON A et al.:Galanin regulates prolactin release and lactotroph proliferation. Proc. Natl. Acad. Sci. USA (1998) 95:12671–12676.
   PubMedGoogle Scholar
• HABERT-ORTOLI E, AMIRANOFF B, LOQUET I, LABURTHE M, MAYAUX JF: Molecular cloning of a functional human galanin receptor. Proc. Nati Acad. Sci. USA (1994) 91:9780–9783.
   PubMed Web of Science ®Google Scholar
• BURGEVIN MC, LOQUET I, QUARTERONET D, HABERT-ORTOLI E: Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor. I MoL Neurosci. (1995) 6:33–41.
   PubMed Web of Science ®Google Scholar
• HOWARD AD, TAN C, SHIAO LL et al.: Molecular cloning and characterization of a new receptor for galanin. FEBS Lett. (1997) 405:285–290.
   PubMed Web of Science ®Google Scholar
• SMITH KE, FORRAY C, WALKER MW et al.: Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J. Biol. Chem. (1997) 272:24612–24616.
   PubMed Web of Science ®Google Scholar
• WANG S, HASHEMI T, HE C, STRADER C, BAYNE M: Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Ma Marmara (1997) 52:337–343.
   Google Scholar
• WANG S, HE C, HASHEMI T, BAYNE M: Cloning and expressional characterization of a novel galanin receptor. Biol. Chem. (1997) 272:31949–31952.
   Google Scholar
• SAKURAI T, AMEMIYA A, ISHII M et al:Orexins and orexin receptors: a family of hypothalamic neuropeptides and G-protein coupled receptors that regulate feeding behaviour. Cell (1998) 92:573–585.
   PubMed Web of Science ®Google Scholar
• PIPER DC, UPTON N, SMITH MI, HUNTER AJ: The novel brain neuropeptide orexin-A modulates the sleep-wake cycle of rats. Eur. I Neurosci. (2000) 12:726–730.
   PubMed Web of Science ®Google Scholar
• DUBE MG, KALRA SP, KALRA PS: Food intake elicited by central administration of orexins: identification of hypothalamic sites of action. Abstract in the 28th annual meeting of socien, for Neuroscience (1998) 24:448(175.8).
   Google Scholar
• SMART D, SABIDO-DAVID C, BROUGH SJ et al.: SB-334867-A: the first selective orexin-1 receptor antagonist. Br. PharmacoL (2001) 132:1179–1182.
   PubMed Web of Science ®Google Scholar
• RODGERS RJ, HALFORD JC, NUNES DE SOUZA RL et al: SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur. Neurosci. (2001) 13:1444–1452.
   PubMed Web of Science ®Google Scholar
• CHEMELLI RIVI, WILLIE JT, SINTON CM et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 98:437–451.
   PubMed Web of Science ®Google Scholar
• QU D, LUDWIG DS, GAMMELTOFT S et al.: A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature (1996) 380:243–247.
   PubMed Web of Science ®Google Scholar
• SHIMADA M, TRITOS NA, LOWELL BB, FLIER JS, MARATOS-FLIER E: Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature (1998) 396:670–674.
   PubMed Web of Science ®Google Scholar
• LUDWIG DS, TRITOS NA, MASTAITIS JW et al.: Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. I Clic]. Invest. (2001) 107:379–386.
   PubMed Web of Science ®Google Scholar
• BACHNER D, KREIENKAMP H, WEISE C, BUCK F, RICHTER D. Identification of melanin concentrating hormone (MCH) as the natural ligand for orphan somatostatin-like receptor 1 (SLC-1). FEBS Lett. (1999) 457:522–524.
   Google Scholar
• CHAMBERS J, AMES RS, BERGSMA D etal.: Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature (1999) 400:261–265.
   Google Scholar
• LEMBO PM, GRAZZINI E, CAO J et al.: The receptor for the orexigenic peptide melanin-concentrating hormone is G-protein-coupled receptor. Nat. Cell Biol. (1999) 1:267–271.
   PubMed Web of Science ®Google Scholar
• SAITO Y, NOTHACKER HP, WANG Z, LIN SH, LESLIE F, CIVELLI 0: Molecular characterization of the melanin-concentrating-hormone receptor. Nature (1999) 400:265–269.
   PubMed Web of Science ®Google Scholar
• AN S, CUTLER G, ZHAO JJ et al.: Identification and characterization of a melanin-concentrating hormone receptor. Proc. Natl. Acad. Sci. USA (2001) 98:7576–7581.
   PubMed Web of Science ®Google Scholar
• HILL J, DUCKWORTH M, MURDOCK P et al.: Molecular cloning and functional characterization of MCH2, a novel human MCH receptor. j Biol. Chem. (2001) 276:20125–20129.
   PubMed Web of Science ®Google Scholar
• MORI M, HARADA M, TERAO Y etal.: Cloning of a novel G protein-coupled receptor, SLT, a subtype of the melanin-concentrating hormone receptor. Biochein. Biophys. Res. Commun. (2001) 283:1013–1018.
   Google Scholar
• SAILER AW, SANO H, ZENG Z et al.: Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc. Nail. Acad. Sci. USA (2001) 98:7564–7569.
   PubMed Web of Science ®Google Scholar
• TSCHOP M, SMILEY DL, HEIMAN ML: Ghrelin induces adiposity in rodents. Nature (2000) 402:908–913.
   Google Scholar
• CONSIDINE RV, SRIHA M, HEILMAN ML et al.: Serum immunoreactive leptin concentration in normal-weight and obese humans. N Engl. J Med. (1996) 334:292–295.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, PESKIND E, RASKIND M et al.: Cerebrospinal fluid leptin level: relationship to plasma levels and adiposity in humans. Nat. Med. (1996) 2:589–593.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1998) 395:763–770.
   PubMed Web of Science ®Google Scholar
• SMITH FJ, CAMPFIELD LA, MOSCHERA JA, BAILON PS, BURN P: Feeding inhibition by neuropeptide Y. Nature (1996) 382:307.
   PubMedGoogle Scholar
• GANTZ I, KONNDA Y, TASHIRO T et al.: Molecular cloning of a novel melanocortin receptor. j Biol. Chem. (1993) 268:8246–8250.
   PubMed Web of Science ®Google Scholar
• GANTZ I, MIWA H, KONDA Y et al.: Molecular cloning, expression, and gene localization of a forth melanocortin receptor. J. Bid. Chem. (1993) 268:15174–15179.
   PubMed Web of Science ®Google Scholar
• ROSELLI-REHFUSS J, MOUNTJOY KG, ROBBINS LS et al.: Identification of a receptor for 7 melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc. Natl. Acad. Li. USA (1993) 90:8856–8860.
   PubMed Web of Science ®Google Scholar
• HUSZAR D, LYNCH CA, FAIRCHILD-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88:131–141.
   PubMed Web of Science ®Google Scholar
• FAN W BOSTON BA, KESTERSON RA, HRUBY VJ, CONE RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature (1997) 385:165–168.
   PubMed Web of Science ®Google Scholar
• OLLMANN MM, WILSON BD, YANG YK et al.: Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science (1997) 278:135–138.
   PubMed Web of Science ®Google Scholar
• SHUTTER JR, GROHAM M, KINSEY AC, SCULLY S, LUTHY R, STARK KL: Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Gene Dev. (1997) 11:593–602.
   PubMed Web of Science ®Google Scholar
• FONG TM, MAO C, MACNEIL T, KALYANI R et al.: ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem. Biophys. Res. Commun. (1997) 237:629–631.
   PubMed Web of Science ®Google Scholar
• NIJENHUIS WA, OOSTEROMJ, ADAN RA: AgRP (83-132) acts as inverse agonist on the human-melanocortin-4 receptor. Ma] Endocrinol. (2001) 15:164–171.
   PubMed Web of Science ®Google Scholar
• MARSH DJ, HOLLOPETER G, KAFER KE, PALMITER RD: Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat. Med. (1998) 4:718–721.
   PubMed Web of Science ®Google Scholar
• KOOB GF, BLOOM FE: Corticotropin-releasing factor and behavior. Fed. Proc. (1985) 44:259–263.
   PubMedGoogle Scholar
• NEMEROFF CB, OWENS MJ, BISSETTE G, ANDORN AC, STANLEY M: Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Cm Psychiatry (1988) 45:577–579.
   PubMed Web of Science ®Google Scholar
• HOTTA M, SHIBASAKI T, ARAI K, DEMURA H: Corticotropin-releasing factor Type 1 mediates emotional stress induced inhibition of food intake and behavioral changes in rats. Brain Res. (1999) 823:221–225.
   PubMed Web of Science ®Google Scholar
• BROWN MR, FISHER LA: in Corticotropin -ReleasingFactor: basic and clinical studies of a neuropeptide. De Souza, EB and Nemeroff CB (Eds.) CRC, Boca Raton, Florida, USA (1990):291–298.
   Google Scholar
• EGAWA M, YOSHIMATSU H, BRAY GA: Preoptic are injection of corticotropin-releasing hormone stimulates sympathetic activity. Am. J. Physic]. (1990) 259:R799–R806.
   Google Scholar
• CHEN R, LEWIS KA, PERRIN MH, VALE WW: Expression cloning of a human corticotropin-releasing factor receptor. Proc. Natl. Acad. Sci. USA (1993) 90:8967–8971.
   PubMed Web of Science ®Google Scholar
• LOVENBERG TW, LIAW CW, GRIGORIADIS DE et a]: Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from the rat brain. Proc. Nat] Acad. Sri. USA (1995) 92:836–840.
   PubMed Web of Science ®Google Scholar
• PERRIN M, DONALDSON C, CHEN R eta].: Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Nail. Acad. Sci. USA (1995) 92:2969–2973.
   Google Scholar
• KOSTICH WA, CHEN A, SPERLE K, LARGENT BL: Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF21 receptor. Mai Eridocnhol. (1998) 12:1077–1085.
   Google Scholar
• SPINA M, MERLO-PICH E, CHAN RKW et al.: Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science (1996) 273:1561–1564.
   PubMed Web of Science ®Google Scholar
• CHALMERS DT, LOVENBERG TW, DE SOUZA EB: Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. Neurosci. (1995) 15:6340–6350.
   Google Scholar
• BEHAN DP, HEINRICHS SC, TRONCOSO JC et a]: Displacement of corticotropin releasing factor from its binding protein as possible treatment for Alzheimer's disease. Nature (1995) 378:284–287.
   PubMedGoogle Scholar
• HEINRICHS SC, LAPSANSKY J, BEHAN DP etal.: Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. Proc. Natl. Acad. Sci. USA (1996) 93:15475–15480.
   Google Scholar
• THIM L, NIELSEN PF, JUDGE ME et al.:Purification and characterization of a new hypothalamic satiety peptide, cocaine and amphetamine regulated transcript (CART), produced in yeast. FEBS Lett. (1998) 428:263–268.
   PubMedGoogle Scholar
• KRISTENSEN P, JUDGE ME, THIM L et al.: Hypothalamic CART is a new anorectic peptide regulated by leptin. Nautre (1998) 393:72–76.
   PubMed Web of Science ®Google Scholar
• MUURAHAINEN NE, KISSILEFF HR, PI-SUNYER FX: Intravenous infusion of bombesin reduces food intake in humans. Am. J. Physic]. (1993) 264:R350–354.
   PubMedGoogle Scholar
• OHKI-HAMAZAKI H, WATASE K, YAMAMOTO K et a]: Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature (1997) 390:165–169.
   PubMed Web of Science ®Google Scholar
• KOPIN AS, MATHES WF, MCBRIDE EW et al.: The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. j Clin. Invest. (1999) 103:383–391.
   PubMed Web of Science ®Google Scholar
• GIBBS J, YOUNG R, SMITH GP: Cholecystokinin decreases food intake in rats. j Comp. Physio] Psycho] (1973) 84:488–493.
   PubMed Web of Science ®Google Scholar
• GIBBS J, FALASCO JD, MCHUGH PR: Cholecystokinin decreases food intake in rhesus monkeys. Am. I Physic] (1976) 230:15–18.
   PubMed Web of Science ®Google Scholar
• ASIN KE, BEDNARZ L, NIKKEL AL et al.: Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide. Am. Physic] (1992) 263:R125–135.
   PubMed Web of Science ®Google Scholar
• MORAN TH, AMEGLIO PJ, PEYTON HJ, SCHWARTZ GJ, MCHUGH PR: Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. Am. j Physic] (1993) 265:R620–R624.
   Google Scholar
• HIRST GC, AQUINO C, BIRKEMO L et al.: Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amini substituent. j Med. Chem. (1996) 39:5236–5245.
   PubMed Web of Science ®Google Scholar
• HENKE BR, AQUINO CJ, BIRKEMO LS et al.: Optimization of 3- (1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent and orally active CCK-A agonists. j Med. Chem. (1997) 40:2706–2725.
   PubMed Web of Science ®Google Scholar
• TURTON MD, O'SHEA D, GUNN I et al.: A role for glucagon-like peptide 1 in the central regulation of feeding. Nature (1996) 379:69–72.
   Google Scholar
• CURZON G, GIBSON EL, OLUYOMI AO: Appetite suppression by commonly used drugs depends on 5-HT receptor, but not on 5-HT availability. Trends Pharmacy] Sci. (1997) 18:21–25.
   PubMed Web of Science ®Google Scholar
• TECOTT LH, SUN LM, AKANA SF et al.: Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (1995) 374:542–546.
   PubMed Web of Science ®Google Scholar
• NONOGAKI K, STRACK AM, DALLMAN MF, TECOTT LH: Leptin-independent hyperphagia and Type 2 diabetes in mice with a mutated serotonin 5-HT2c receptor gene. Nat. Med. (1998) 4:1152–1156.
   PubMed Web of Science ®Google Scholar
• BOS M, JENCK F, MARTIN JR et a/.: Novel agonists of 5-HT2c receptors. Synthesis and biological evaluation of substituted 2-(indol-y1)-1-methylethylamines and 2- (indeno [1,2-b[pyrrol 1 yl) 1 methylethylamines. Improved therapeutics for obsessive compulsive disorder. j Med. Chem. (1997) 40:2762–2769.
   Google Scholar
• ISAAC M, SLASSI A, O'BRIEN A et al.: Pyrrolo[3,2,1-ifiquinoline derivatives, a 5-HT2c receptor agonist with selectivity over the 5-HT 2A receptor: potential therapeutic applications for epilepsy and obesity. Bioorg. Med. Chem. Lett. (2000) 19:919–921.
   Google Scholar
• CLIFTON PG, LEE MD, DOURISH CT: Similarities in the action of Ro60-0175, a 5-HT2c receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology (2000) 152:256–267.
   PubMed Web of Science ®Google Scholar
• MATTSON MP: Lose weight STAT: CNTF tops leptin. Trend Neurosci. (2001) 24:313:314.
   PubMedGoogle Scholar
• ERICKSON JC, CLEGG KE, PALMITER RD: Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (1996) 381:415–418.
   PubMed Web of Science ®Google Scholar
• PEDRAZZINI T, SEYDOUX J, KUNSTNER P: Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat. Med. (1998) 4:722–726.
   PubMed Web of Science ®Google Scholar
• MARSH DJ, HOLLOPETER G, HUSZAR D et al: Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat. Genetics (1999) 21:119–122.
   PubMed Web of Science ®Google Scholar
• BLUNDELL JE: Serotonin and the biology of feeding. Am. j Chia. Num (1992) 55:155S–159S
   Google Scholar